The9 Investee Nanyang Biologics (NYB) Advancing Planned Nasdaq Listing for the US$1.5 Billion Business Combination
The9 Limited (Nasdaq: NCTY) said its investee Nanyang Biologics (NYB) received SEC effectiveness notice for its Form F-4 tied to a planned Nasdaq listing under ticker NYB. The business combination values NYB at about US$1.5 billion. The9 expects its subsidiary Gamenow to own 15% to 16% post-closing, subject to an Aug. 19, 2026 vote and Nasdaq approval.
How this was made
The 30-second read
Why it matters
SEC notice of effectiveness for NYB’s Form F-4 reduces regulatory friction and can improve perceived probability of closing, but completion still depends on the SPAC extraordinary general meeting outcome and Nasdaq approval.
Market read
This is a concrete deal-progress update tied to a regulatory filing milestone, with a near-term catalyst window around the Aug. 19 shareholder vote.
What to watch
The article does not provide financial performance, cash needs, or deal terms beyond valuation and expected ownership, limiting how far the news can move fundamentals.
Background
The9 is advancing its Singapore investee Nanyang Biologics (NYB) toward a planned Nasdaq listing via a previously announced business combination.
Ticker impact
The9 says NYB’s SEC Form F-4 registration statement is effective, advancing NYB’s planned Nasdaq listing and The9’s expected 15% to 16% stake.
Near-term upside bias for NCTY on deal-progress headlines, with volatility around the Aug. 19 extraordinary general meeting and Nasdaq approval.
The article discloses a concrete regulatory milestone (SEC notice of effectiveness) plus deal mechanics (valuation, expected ownership, and key gating events), which can re-rate perceived completion probability.
Market effects
Highlights continued capital-market activity for AI drug discovery platforms and natural-compound discovery models, potentially supportive for sentiment toward adjacent biotech AI themes.
Primarily US listing and SEC process, with secondary sentiment spillover to Singapore-based biotech deal flow.
US regulatory milestone (SEC effectiveness) can influence cross-border investor appetite for similar SPAC-to-Nasdaq structures.
Counterpoint
Even with SEC effectiveness, the transaction remains contingent on the Aug. 19 vote and Nasdaq approval, so the market may already price much of the progress.
Key entities
- public_companyThe9 Limited
Nasdaq-listed parent expected to own 15% to 16% of the combined company after NYB’s planned Nasdaq listing.
- private_companyNanyang Biologics Pte. Ltd. (NYB)
Singapore-headquartered AI-first drug discovery company seeking Nasdaq listing under reserved ticker symbol NYB.
- regulatorSEC
Provided notice of effectiveness for NYB’s Form F-4 registration statement.
- corporate_eventSPAC extraordinary general meeting
Scheduled for Aug. 19, 2026, and required for the business combination to proceed.
